CSPC Pharmaceutical (HKG:1093) has obtained approval to conduct a clinical trial of Prusogliptin and Metformin Extended-Release Tablets from China's National Medical Products Administration, a Tuesday filing with the Hong Kong bourse said.
The indication for the trial approval is for use as an adjunct to diet and exercise in the treatment of adult patients with type 2 diabetes mellitus.
The product is the world's first fixed-dose combination formulation of prusogliptin and metformin hydrochloride approved for clinical trials.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。